行情

IONS

IONS

Isis Pharms
NASDAQ

实时行情|Nasdaq Last Sale

62.96
+0.25
+0.40%
交易中 09:46 09/23 EDT
开盘
62.13
昨收
62.71
最高
63.00
最低
62.11
成交量
5.74万
成交额
--
52周最高
86.58
52周最低
43.27
市值
88.46亿
市盈率(TTM)
21.96
分时
5日
1月
3月
1年
5年

分析师评级

16位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

IONS 新闻

  • 沙特复产速度遭质疑 美油重上60美元仍可期
  • 汇通网.4小时前
  • 比亚迪:在德国斩获22台12米纯电动大巴订单
  • 新浪财经综合.4小时前
  • 欧元区经济增长接近停滞 制造业重挫的影响开始蔓延
  • 新浪财经综合.4小时前
  • 欧央行实现通胀目标之路 或事与愿违制造"减码恐慌"
  • 新浪财经综合.4小时前

更多

所属板块

生物技术和医学研究
+0.11%
制药与医学研究
+0.09%

热门股票

名称
价格
涨跌幅

IONS 简况

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
展开

Webull提供Ionis Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。